Skip to main content
. 2021 Nov 24;40(2):127–137. doi: 10.1200/JCO.21.02229

FIG 5.

FIG 5.

PFS in patients (A) with or (B) without baseline liver metastases and OS in patients (C) with or (D) without baseline liver metastases. Patients were followed for a minimum of 77 months. aDescriptive analysis. HR, hazard ratio; NR, not reached; OS, overall survival; PFS, progression-free survival.